PTEN and neoplasm: Whole-genome sequencing of tumor and germline DNA samples from 92 patients with primary refractory and paired sensitive and resistant tumors reported inactivating mutations of TSGs, including RB1, NF1, RAD51B, and PTEN in resistant tumors (158).